492 results
P
Women
I/C
High mammographic density (MD), Low mammographic density (MD)
O
Increased risk of breast cancer subtypes, specifically HER-2 positive cancers
P
people with a history of cardiovascular disease (CVD)
I/C
adherence to Mediterranean diet (MD), a 2-unit increment in MD score
O
all-cause and cardiovascular mortality
P
694 participants, 1012 participants
I/C
Bilingualism, Monolingualism
O
Symptoms (MD 4.05 years, 95% CI: 1.87-6.22), Diagnosis (MD 2.0 years, 95% CI: 0.08-3.92)
P
Nordic hamstring exercise (NHE)
I/C
training programs involving the NHE
O
mean difference (MD) or standardized change of mean difference (SCMD)
P
3,697 participants
I/C
women-focused cardiac rehabilitation (CR), active comparison group
O
functional capacity, physical (MD=6.37, 95% CI=3.14-9.59)
P
type 2 diabetes mellitus (T2DM) patients at low risk of cardiovascular diseases
I/C
first-line use of sodium-dependent glucose transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), placebo, metformin
O
glycosylated hemoglobin type A1C (HbA1c) levels, weight, fasting plasma glucose (FPG) levels
P
patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA)
I/C
intravenous (IV) or intra-articular (IA) administration of tranexamic acid (TXA), IV vs. IA administration of TXA
O
venous thromboembolisation, total blood loss, drain output, hidden blood loss, postoperative haemoglobin level, haemoglobin drop, blood transfusion rate, total adverse events, postoperative range of motion, postoperative VAS pain score, postoperative D-dimer level, length of hospital stay
P
patients with diabetic kidney disease
I/C
acupuncture
O
clinical effective rate, high-density lipoprotein cholesterol, urinary albumin, urinary microalbumin, urine β2-microglobulin, serum creatinine, glycated hemoglobin A1c, fasting blood glucose, 2h postprandial plasma glucose, total cholesterol, triglyceride
P
patients with polycystic ovary syndrome (PCOS)
I/C
curcumin, placebo
O
glycemic control, lipid profile
P
697 participants
I/C
Dexmedetomidine, Control group
O
Pain scores in PACU, Pain scores on POD1, IVME in PACU, IVME on POD1, PONV in PACU, PONV on POD1, LOS, Intraoperative MAP, Intraoperative HR